NDA 215499 · Viiv Hlthcare
Apretude
Cabotegravir · Intramuscular
Breakthrough therapyPriority reviewLast checked: Nov 19, 2026Latest source record: Apr 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 20, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
97
26 Phase 3, 19 recruiting
FAERS reports
8,201
1,642 serious, 105 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE‑EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION Individuals must be tested for HIV-1 infection prior to initiating APRETUDE or oral cabotegravir, and with each subsequent injection of APRETUDE, using a test approved or cleared by the FDA for the diagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1 variants have been identified with use of APRETUDE by individuals with undiagnosed HIV-1 infection. Do not initiate APRETUDE for HIV-1 PrEP unless negative infection status is confirmed. Individuals who acquire HIV-1 while receiving APRETUDE for PrEP must transition to a complete HIV-1 treatment regimen [see Dosage and Administration ( 2.2 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN...
What it is approved for
From the label in effect Apr 11, 2025.
APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration ( 2.2 , 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. ( 1 )
Mechanism: Cabotegravir is an HIV-1 antiretroviral drug [see Microbiology ( 12.4 )] in a long-acting formulation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 20, 2024 Supplement 8 · Efficacy LetterLabel
- Dec 20, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyLabelLetterReview
1 products under this application
- APRETUDE · CABOTEGRAVIR 600MG/3ML (200MG/ML) · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabotegravir" as an intervention, any sponsor and status, largest first.
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With MenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02720094 · 4,570 participants · Start Dec 19, 2016 · Primary completion May 14, 2020
Drug: Cabotegravir Oral Tablet; TDF/FTC tablets and 4 more · For: HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 43 sites in all
- Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected WomenPivotal-lookingActive, not recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03164564 · 3,224 participants · Start Nov 7, 2017 · Primary completion Nov 5, 2020
Drug: Oral CAB; Oral TDF/FTC and 4 more · For: HIV Infections
Sites: Gaborone, Botswana; Mbabane, Eswatini; Kisumu, Kenya · 20 sites in all
- Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Pivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT06134362 · 2,998 participants · Start May 14, 2024 · Primary completion Mar 14, 2029
Drug: CAB LA · For: HIV Infections
Sites: Almagro, Argentina; Buenos Aires, Argentina; Francistown, Botswana · 33 sites in all
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTPivotal-lookingRecruiting
Africa Health Research InstituteAcademic, hospital or other
NCT06250504 · 2,052 participants (planned) · Start Feb 27, 2024 · Primary completion Apr 30, 2026
Drug: APRETUDE (cabotegravir) 600 mg\3 mL; DAPIRING (Dapivirine) 25mg Vaginal Ring and 2 more · For: HIV Infections
Sites: Somkele, South Africa
- The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirPivotal-lookingStatus unknown
Evandro Chagas National Institute of Infectious DiseaseAcademic, hospital or other
NCT05515770 · 1,200 participants (planned) · Start Sep 20, 2022 · Primary completion Oct 2025
Drug: Cabotegravir Injection · For: HIV Infections
Sites: Rio de Janeiro, Brazil
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsPivotal-lookingActive, not recruiting
ViiV HealthcareGSK (GSK)
NCT03299049 · 1,049 participants · Start Oct 27, 2017 · Primary completion Jun 6, 2019
Drug: Cabotegravir Tablets; Rilpivirine Tablets and 2 more · For: HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 119 sites in all
- SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT05549726 · 984 participants · Start Jan 2, 2023 · Primary completion Dec 18, 2023
Drug: Cabotegravir Injectable Suspension · For: HIV
Sites: Kisumu, Kenya; Mbarara, Uganda
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue1,128
- off label use1,050
- injection site pain943
- viral load increased434
- pain414
- virologic failure270
- pyrexia259
- inappropriate schedule of product administration257
- product use in unapproved therapeutic environment254
- pathogen resistance251
- product complaint240
- drug ineffective236
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 16 |
| 2018 | 7 |
| 2019 | 22 |
| 2020 | 38 |
| 2021 | 253 |
| 2022 | 997 |
| 2023 | 1,934 |
| 2024 | 2,656 |
| 2025 | 1,752 |
| 2026 | 524 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Apretude (Cabotegravir)
2024 spending
$12.8M
Beneficiaries
996
3,358 claims
Per beneficiary
$12,875
$1,270.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $2,684,050 |
| 2023 | $10,681,954 |
| 2024 | $12,823,732 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Equivalence Trial
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
Landovitz RJ, Donnell D, Clement ME, et al. · N Engl J Med 2021 · Comparative Study, Equivalence Trial
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, et al. · Lancet 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.